Pharma’s Ageism Problem: Why Are We Pushing Out the Experience We Need Most?

Group of young coworkers smiling and discussing by a whiteboard while an older woman appears concerned at her office desk

The pharma industry is experiencing one of the most challenging periods in its history. Drug-development costs are increasing. Pricing pressure is mounting. Regulatory scrutiny is escalating. Patent cliffs loom. Artificial intelligence is transforming how work is performed, and patients, policymakers, and investors are demanding that companies operate with greater speed, efficiency, and value. At a time when seasoned expertise is required, pharma companies are pushing out seasoned employees. Then, when those same employees want to return, the companies won’t hire them back. While this issue is rarely acknowledged publicly, the reality cannot be ignored: There is ageism in the pharma industry.

Experience Is Being Treated as an Expense

Corporate restructurings are often couched in sterile terms: transformation, simplification, delayering or cost optimization. But behind those phrases are often middle and senior employees who have spent years – even decades – building scientific, commercial and organizational knowledge. They have shepherded product launches.

Weathered regulatory disappointments. Fought patent challenges. Negotiated with payers. Managed recalls. Led teams through reorganizations and leadership changes. They know what worked. They know what failed. And – perhaps most importantly – they know why.

But long-time employees can look costly on a balance sheet. They may command higher salaries. They may question short-sighted assumptions. They may have been around when the last “innovative new strategy” was implemented – and quietly ignored. When businesses take cost-cutting too far, institutional knowledge is often treated like overhead.

The result is an unfortunate trend: Middle and senior-level employees are pressured to retire, targeted during layoffs, or overshadowed by “fresh” graduates and young professionals. Once displaced, many learn that their years of experience have become liabilities instead of assets.

They read or hear comments like these: “You’re overqualified.” “We’re looking for someone with a different vibe.” “We need someone who can grow with the company.” “It scares us that you might become bored in this role.” Just because something is subtle doesn’t mean that it isn’t discrimination.

The Industry Is Creating Its Own Experience Gap

Pharma companies often lament their inability to find enough qualified candidates. At the same time, capable people in their 50s and 60s are told, “We just can’t find you interviews.” This is not a talent shortage. It’s a failure to see talent.

A resume with 25 or 30 years of experience should signal resilience, pattern recognition, and judgment forged in the fires of experience. Instead, recruiters see higher salary expectations, obsolete skills, or someone who will leave before their value is realized. Rarely are these assumptions challenged.

The experienced candidate may be flexible, tech-savvy, and ready to tackle whatever is asked of them. The younger candidate may depart after two years. Age can reveal nothing about a person’s curiosity, energy, dedication or potential performance. The irony is that pharma judges its products and services based on benefits to older patients every day. There are huge investments spent on improving the lives of people with cancer, cardiovascular disease, diabetes and neurological disorders. These diseases tend to affect people as they get older, yet Pharma discriminates against people as they get older. If you want to sell pharmaceuticals, don’t treat longevity as a liability.

Experience and Innovation Are Not Opposites

One of the most enduring misconceptions driving ageism in the workplace is that young workers equal innovation and older workers equal the past. Innovation is not a function of age. It is a function of curiosity, imagination, expertise, and the desire to challenge assumptions.

Veteran employees see patterns that others may overlook. They know how decisions cascade through an organization and where well-intentioned strategies can get stalled. They understand a new product is not guaranteed to succeed simply because it gains regulatory approval. It still must win over physicians, patients, payers and internal budgets.

Young employees offer invaluable new perspectives, technical skills and different expectations about work. Older employees offer context, judgment and experience derived from facing complex issues again and again. Companies need both. The solution is not to privilege one age group over another. Instead, we should build truly multigenerational teams where knowledge transfers in both directions.

What Pharma Leaders Should Do

Having an “age” addition to your diversity statement won’t solve ageism. Evaluate who’s getting picked for layoffs. Who’s getting interviews. Who’s making it past round one of the interview process. Train recruiters and hiring managers to understand assumptions around age that are often masked by “culture fit,” “energy,” or “overqualified”.

Job descriptions shouldn’t have qualifiers that scare away seasoned professionals. Build opportunities for older workers to continue contributing via staff roles, advisory councils, project-based work, mentoring and fractional leadership.

Finally, stop penalizing people for having experience. Experience is often the first thing to go when companies begin cost-cutting. Institutional knowledge is silent. You don’t realize its value until it’s gone. When a mistake that was made before gets repeated. When you lose a relationship that no one knew existed. When someone makes a decision without knowing the why or how behind it.

The Industry Cannot Afford This Blind Spot

Ageism is not simply unfair to older workers. It is bad business.

Pharma companies are navigating problems that cannot be solved by enthusiasm alone. They require scientific understanding, commercial judgment, organizational memory and the confidence to challenge fashionable thinking.

Those qualities often take decades to develop. If the industry continues pushing out senior professionals while claiming it cannot find the talent needed to meet today’s challenges, it should stop blaming the labor market. The experience is available.

The real question is whether pharma companies are willing to recognize it.

About Richard Meyer

I’m Richard Meyer — a 25 year healthcare marketing strategist and writer focused on the intersection of direct-to-consumer marketing, healthcare economics, and human behavior.I started Work of DTC Marketing because too much of the conversation around pharma and healthcare marketing is either overly promotional, overly technical, or completely disconnected from how the system actually works.Here, I write about what DTC really does, how incentives drive behavior inside healthcare organizations, why patients are often treated like revenue streams instead of people, and why “best practices” are frequently just recycled assumptions.My background spans digital marketing, public relations, and healthcare strategy, and my approach is pragmatic, skeptical of hype, and grounded in data and lived experience. I’m less interested in what sounds good in a deck and more interested in what actually changes outcomes — for companies, doctors, and especially patients.

View all posts by Richard Meyer →

Leave a Reply